Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy

NCT01647971 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT01647971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01647971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 19, 2012
Completion date
May 31, 2015
Enrollment
39 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, chronic lymphocytic leukemia (cll), marginal zone lymphoma, non-hodgkins lymphoma, primary central nervous system lymphoma, small lymphocytic lymphoma (sll), waldenstrom's macroglobulinemia